News | November 16, 2025
Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
SMDC is a participating authority under Pharmaceutical Inspection Cooperation Scheme (PIC/S)
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Subscribe To Our Newsletter & Stay Updated
